Literature DB >> 1716285

IL-8 inhibits histamine release from human basophils induced by histamine-releasing factors, connective tissue activating peptide III, and IL-3.

P Kuna1, S R Reddigari, D Kornfeld, A P Kaplan.   

Abstract

We have previously purified and partially characterized histamine releasing factors (HRF), which were derived from a mixture of human mononuclear cells and platelets. We now report the effect of IL-8 upon HRF-, connective tissue activating peptide III (CTAP III)-, and IL-3-induced histamine release from human basophils. We determined that IL-8 itself, at concentrations between 10(-7) to 10(-11) M, does not release histamine from basophils, although positive results are observed in two of 26 subjects at 10(-7) M. Unfractionated (crude) HRF released histamine in 25 of 26 donors, in the range of 6.7% to 100% of total basophil histamine stores. When basophils were preincubated with IL-8 (10(-7) to 10(-11) M) for 5 min, followed by a 40-min incubation with HRF, histamine release was significantly inhibited in 20 of 25 donors. Inhibition was observed at as little as 10(-11) M IL-8, with maximal inhibition being attained at 10(-9) M. HRF-containing supernatants contain a mixture of different histamine-releasing moieties. To better define which factor(s) may be inhibited by IL-8, fractionated supernatants, purified CTAP III, and IL-3 were studied. Histamine release produced by two different HRF-containing chromatographic fractions (HRFvoid and HRFpeak 2) and purified CTAP-III (5 micrograms/ml) was inhibited by IL-8 in 10 of 12 donors, three of three donors, and seven of 10 donors, respectively. IL-3 (5000 U/ml)-dependent histamine release was inhibited by IL-8 in all subjects tested. In contrast, histamine release by anti-IgE and FMLP was not affected by IL-8. Thus, IL-8 appears to be an inhibitor of cytokine-like molecules that induce histamine release and may represent the previously described 8-kDa histamine release inhibitory factor present in mononuclear cell supernatants.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716285

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  IgE-dependent histamine-releasing factors.

Authors:  H A Sampson; S M MacDonald
Journal:  Springer Semin Immunopathol       Date:  1993

Review 2.  Chemokines and tissue injury.

Authors:  M B Furie; G J Randolph
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

3.  Chondroitin sulphate inhibits connective tissue mast cells.

Authors:  T C Theoharides; P Patra; W Boucher; R Letourneau; D Kempuraj; G Chiang; S Jeudy; L Hesse; A Athanasiou
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

Review 4.  Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy.

Authors:  P Uotila
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

5.  Characterization of histamine-releasing activity: role of cytokines and IgE heterogeneity.

Authors:  T N Liao; K H Hsieh
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

6.  Detection of plasma interleukin-8 in atopic dermatitis.

Authors:  H Kimata; I Lindley
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

7.  NF-kappa B subunit-specific regulation of the interleukin-8 promoter.

Authors:  C Kunsch; C A Rosen
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

8.  Interleukin-8 and RANTES induce the adhesion of the human basophilic cell line KU-812 to human endothelial cell monolayers.

Authors:  K B Bacon; L Flores-Romo; J P Aubry; T N Wells; C A Power
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

9.  Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils.

Authors:  P Kuna; S R Reddigari; D Rucinski; J J Oppenheim; A P Kaplan
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.